FDA Clears Spectral AI's DeepView System for Burn Care, Paving Way for Commercial Launch
Summary
Spectral AI has received FDA De Novo Classification for its DeepView System for burn indication, allowing immediate commercial distribution in the United States. This is a critical regulatory milestone for the company's core predictive AI medical device. The clearance follows earlier positive clinical trial results and significant non-dilutive funding from BARDA. This development is crucial, especially after the company reported a sharp decline in Q1 2026 revenue and increased cash burn, providing a clear path to revenue generation and addressing recent financial concerns.
At the time of this announcement, MDAI was trading at $2.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.3M. The 52-week trading range was $1.18 to $3.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.